415 related articles for article (PubMed ID: 24240700)
1. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Bajrami I; Frankum JR; Konde A; Miller RE; Rehman FL; Brough R; Campbell J; Sims D; Rafiq R; Hooper S; Chen L; Kozarewa I; Assiotis I; Fenwick K; Natrajan R; Lord CJ; Ashworth A
Cancer Res; 2014 Jan; 74(1):287-97. PubMed ID: 24240700
[TBL] [Abstract][Full Text] [Related]
2. C16orf72/HAPSTR1/TAPR1 functions with BRCA1/Senataxin to modulate replication-associated R-loops and confer resistance to PARP disruption.
Sharma AB; Ramlee MK; Kosmin J; Higgs MR; Wolstenholme A; Ronson GE; Jones D; Ebner D; Shamkhi N; Sims D; Wijnhoven PWG; Forment JV; Gibbs-Seymour I; Lakin ND
Nat Commun; 2023 Aug; 14(1):5003. PubMed ID: 37591890
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method.
Reiner T; Keliher EJ; Earley S; Marinelli B; Weissleder R
Angew Chem Int Ed Engl; 2011 Feb; 50(8):1922-5. PubMed ID: 21328671
[No Abstract] [Full Text] [Related]
4. Alkylation of nucleobases by 2-chloro-
Wie M; Khim KW; Groehler Iv AS; Heo S; Woo J; Son K; Lee EA; Ra JS; Hong SY; Schärer OD; Choi JH; Myung K
NAR Cancer; 2023 Sep; 5(3):zcad042. PubMed ID: 37554969
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer.
Naidoo K; Wai PT; Maguire SL; Daley F; Haider S; Kriplani D; Campbell J; Mirza H; Grigoriadis A; Tutt A; Moseley PM; Abdel-Fatah TMA; Chan SYT; Madhusudan S; Rhaka EA; Ellis IO; Lord CJ; Yuan Y; Green AR; Natrajan R
Mol Cancer Ther; 2018 Jan; 17(1):306-315. PubMed ID: 29133620
[TBL] [Abstract][Full Text] [Related]
6. Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers.
Kossatz S; Pirovano G; Demétrio De Souza França P; Strome AL; Sunny SP; Zanoni DK; Mauguen A; Carney B; Brand C; Shah V; Ramanajinappa RD; Hedne N; Birur P; Sihag S; Ghossein RA; Gönen M; Strome M; Suresh A; Molena D; Ganly I; Kuriakose MA; Patel SG; Reiner T
Nat Biomed Eng; 2020 Mar; 4(3):272-285. PubMed ID: 32165735
[TBL] [Abstract][Full Text] [Related]
7. High-yielding, two-step 18F labeling strategy for 18F-PARP1 inhibitors.
Keliher EJ; Reiner T; Turetsky A; Hilderbrand SA; Weissleder R
ChemMedChem; 2011 Mar; 6(3):424-7. PubMed ID: 21360818
[No Abstract] [Full Text] [Related]
8. Synthetic Lethality through the Lens of Medicinal Chemistry.
Myers SH; Ortega JA; Cavalli A
J Med Chem; 2020 Dec; 63(23):14151-14183. PubMed ID: 33135887
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Model for High-Grade Neuroendocrine Carcinoma of the Lung Incorporating Genomic Profiling and Poly (ADP-ribose) Polymerase-1 Expression.
Kim HS; Kim JK; Lee JH; Lee YJ; Lee GK; Han JY
JCO Precis Oncol; 2024 Apr; 8():e2300495. PubMed ID: 38635931
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.
Joshi PM; Sutor SL; Huntoon CJ; Karnitz LM
J Biol Chem; 2014 Mar; 289(13):9247-53. PubMed ID: 24554720
[TBL] [Abstract][Full Text] [Related]
11. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex.
Ekumi KM; Paculova H; Lenasi T; Pospichalova V; Bösken CA; Rybarikova J; Bryja V; Geyer M; Blazek D; Barboric M
Nucleic Acids Res; 2015 Mar; 43(5):2575-89. PubMed ID: 25712099
[TBL] [Abstract][Full Text] [Related]
12. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
[TBL] [Abstract][Full Text] [Related]
13. Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.
Popova T; Manié E; Boeva V; Battistella A; Goundiam O; Smith NK; Mueller CR; Raynal V; Mariani O; Sastre-Garau X; Stern MH
Cancer Res; 2016 Apr; 76(7):1882-91. PubMed ID: 26787835
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.
Natrajan R; Wilkerson PM; Marchiò C; Piscuoglio S; Ng CK; Wai P; Lambros MB; Samartzis EP; Dedes KJ; Frankum J; Bajrami I; Kopec A; Mackay A; A'hern R; Fenwick K; Kozarewa I; Hakas J; Mitsopoulos C; Hardisson D; Lord CJ; Kumar-Sinha C; Ashworth A; Weigelt B; Sapino A; Chinnaiyan AM; Maher CA; Reis-Filho JS
J Pathol; 2014 Apr; 232(5):553-65. PubMed ID: 24395524
[TBL] [Abstract][Full Text] [Related]
15. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.
Lord CJ; Tutt AN; Ashworth A
Annu Rev Med; 2015; 66():455-70. PubMed ID: 25341009
[TBL] [Abstract][Full Text] [Related]
16. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Mateo J; Carreira S; Sandhu S; Miranda S; Mossop H; Perez-Lopez R; Nava Rodrigues D; Robinson D; Omlin A; Tunariu N; Boysen G; Porta N; Flohr P; Gillman A; Figueiredo I; Paulding C; Seed G; Jain S; Ralph C; Protheroe A; Hussain S; Jones R; Elliott T; McGovern U; Bianchini D; Goodall J; Zafeiriou Z; Williamson CT; Ferraldeschi R; Riisnaes R; Ebbs B; Fowler G; Roda D; Yuan W; Wu YM; Cao X; Brough R; Pemberton H; A'Hern R; Swain A; Kunju LP; Eeles R; Attard G; Lord CJ; Ashworth A; Rubin MA; Knudsen KE; Feng FY; Chinnaiyan AM; Hall E; de Bono JS
N Engl J Med; 2015 Oct; 373(18):1697-708. PubMed ID: 26510020
[TBL] [Abstract][Full Text] [Related]
17. Role and therapeutic potential of CDK12 in human cancers.
Chilà R; Guffanti F; Damia G
Cancer Treat Rev; 2016 Nov; 50():83-88. PubMed ID: 27662623
[TBL] [Abstract][Full Text] [Related]
18. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.
Liang K; Gao X; Gilmore JM; Florens L; Washburn MP; Smith E; Shilatifard A
Mol Cell Biol; 2015 Mar; 35(6):928-38. PubMed ID: 25561469
[TBL] [Abstract][Full Text] [Related]
19. [Function of CDK12 in Tumor initiation and progression and its clinical consequences].
Vrábel D; Svoboda M; Navrátil J; Kohoutek J
Klin Onkol; 2014; 27(5):340-6. PubMed ID: 25312711
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
